Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells - PubMed (original) (raw)
doi: 10.1038/nm871. Epub 2003 May 12.
Affiliations
- PMID: 12740570
- DOI: 10.1038/nm871
Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells
Michele De Palma et al. Nat Med. 2003 Jun.
Abstract
Angiogenic tumor vessels are promising targets for the activity and the selective delivery of cancer therapeutics. The bone marrow contributes different cell types to the tumor stroma, including hematopoietic cells and, as recently suggested, vascular endothelial cells (ECs). Thus, transplantation of genetically modified bone marrow progenitors may represent a vehicle for the transport of gene therapy to tumors. We transduced bone marrow progenitors with lentiviral vectors expressing genes from transcription-regulatory elements of Tie2/Tek gene. When tumors were grown in the transplanted mice, the new vector marked a distinct hematopoietic population that 'homed' to the tumor and closely interacted with vascular ECs at the tumor periphery. These Tie2-expressing mononuclear (TEM) cells had a distinguishable phenotype and were present selectively at angiogenic sites. Unexpectedly, we did not find bone marrow-derived ECs in tumor vessels when we transplanted bone marrow progenitors constitutively expressing a marker gene from the Tie2 or ubiquitously active promoters. By delivering a 'suicide' gene, we selectively eliminated the TEM cells and achieved substantial inhibition of angiogenesis and slower tumor growth without systemic toxicity. Thus, TEM cells may account for the proangiogenic activity of bone marrow-derived cells in tumors, may represent a new target for drug development and may provide the means for selective gene delivery and targeted inhibition of tumor angiogenesis.
Similar articles
- In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors.
De Palma M, Venneri MA, Naldini L. De Palma M, et al. Hum Gene Ther. 2003 Aug 10;14(12):1193-206. doi: 10.1089/104303403322168028. Hum Gene Ther. 2003. PMID: 12908970 - Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice.
Davidoff AM, Ng CY, Brown P, Leary MA, Spurbeck WW, Zhou J, Horwitz E, Vanin EF, Nienhuis AW. Davidoff AM, et al. Clin Cancer Res. 2001 Sep;7(9):2870-9. Clin Cancer Res. 2001. PMID: 11555605 - Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.
De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L. De Palma M, et al. Cancer Cell. 2005 Sep;8(3):211-26. doi: 10.1016/j.ccr.2005.08.002. Cancer Cell. 2005. PMID: 16169466 - Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy?
De Palma M, Naldini L. De Palma M, et al. Biochim Biophys Acta. 2009 Aug;1796(1):5-10. doi: 10.1016/j.bbcan.2009.04.001. Epub 2009 Apr 10. Biochim Biophys Acta. 2009. PMID: 19362584 Review. - Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications.
De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE. De Palma M, et al. Trends Immunol. 2007 Dec;28(12):519-24. doi: 10.1016/j.it.2007.09.004. Epub 2007 Nov 5. Trends Immunol. 2007. PMID: 17981504 Review.
Cited by
- Mechanisms of angiogenesis in tumour.
Zhang R, Yao Y, Gao H, Hu X. Zhang R, et al. Front Oncol. 2024 Mar 25;14:1359069. doi: 10.3389/fonc.2024.1359069. eCollection 2024. Front Oncol. 2024. PMID: 38590656 Free PMC article. Review. - Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism.
Yang F, Lee G, Fan Y. Yang F, et al. Angiogenesis. 2024 Aug;27(3):333-349. doi: 10.1007/s10456-024-09913-z. Epub 2024 Apr 6. Angiogenesis. 2024. PMID: 38580870 Free PMC article. Review. - Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy.
Kang X, Huang Y, Wang H, Jadhav S, Yue Z, Tiwari AK, Babu RJ. Kang X, et al. Pharmaceutics. 2023 Dec 29;16(1):61. doi: 10.3390/pharmaceutics16010061. Pharmaceutics. 2023. PMID: 38258072 Free PMC article. Review. - Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy.
Ghasemi A, Martinez-Usatorre A, Li L, Hicham M, Guichard A, Marcone R, Fournier N, Torchia B, Martinez Bedoya D, Davanture S, Fernández-Vaquero M, Fan C, Janzen J, Mohammadzadeh Y, Genolet R, Mansouri N, Wenes M, Migliorini D, Heikenwalder M, De Palma M. Ghasemi A, et al. Nat Cancer. 2024 Feb;5(2):240-261. doi: 10.1038/s43018-023-00668-y. Epub 2023 Nov 23. Nat Cancer. 2024. PMID: 37996514 Free PMC article. - Cellular heterogeneity and stem cells of vascular endothelial cells in blood vessel formation and homeostasis: Insights from single-cell RNA sequencing.
Wakabayashi T, Naito H. Wakabayashi T, et al. Front Cell Dev Biol. 2023 Mar 21;11:1146399. doi: 10.3389/fcell.2023.1146399. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37025170 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous